{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:07:51Z","timestamp":1789157271840,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ard.2026.03.030","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:00:10Z","timestamp":1777579210000},"page":"1854-1865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of tofacitinib on growth in patients with juvenile idiopathic arthritis"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-2987","authenticated-orcid":false,"given":"Hermine I.","family":"Brunner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mittermayer","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila K.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviane Angelina","family":"De Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Houghton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clovis A.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Terreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Cuttica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muammer Hakan","family":"Poyrazoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halley M.","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Saul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine I.","family":"Soderstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Vranic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Yndestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahta","family":"Mortezavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolino","family":"Ruperto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ard.2026.03.030_bib0001","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-021-00332-8","article-title":"Juvenile idiopathic arthritis","volume":"8","author":"Martini","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.ard.2026.03.030_bib0002","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12969-021-00521-5","article-title":"Growth and puberty in children with juvenile idiopathic arthritis","volume":"19","author":"d'Angelo","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"issue":"2","key":"10.1016\/j.ard.2026.03.030_bib0003","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/acr.24065","article-title":"Growth and puberty in juvenile dermatomyositis: a longitudinal cohort study","volume":"72","author":"Nordal","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.ard.2026.03.030_bib0004","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/annrheumdis-2011-200106","article-title":"A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus","volume":"71","author":"Rygg","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ard.2026.03.030_bib0005","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1007\/s10620-021-07091-2","article-title":"Growth delay in inflammatory bowel diseases: the importance of surgery","volume":"66","author":"Parra","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.ard.2026.03.030_bib0006","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1210\/er.2015-1026","article-title":"Growth and the growth hormone-insulin like growth factor 1 axis in children with chronic inflammation: current evidence, gaps in knowledge, and future directions","volume":"37","author":"Wong","year":"2016","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ard.2026.03.030_bib0007","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3389\/fendo.2018.00794","article-title":"Osteocalcin-a versatile bone-derived hormone","volume":"9","author":"Moser","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"10.1016\/j.ard.2026.03.030_bib0008","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1515\/CCLM.2001.159","article-title":"Pediatric reference ranges for osteocalcin measured by the Immulite analyzer","volume":"39","author":"Seydewitz","year":"2001","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"10.1016\/j.ard.2026.03.030_bib0009","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00774-004-0544-9","article-title":"The relationships between pubertal development, IGF-1 axis, and bone formation in healthy adolescents","volume":"23","author":"Kanbur","year":"2005","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"10.1016\/j.ard.2026.03.030_bib0010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13098-023-01021-0","article-title":"Age- and sex-specific differences in the association of serum osteocalcin and cardiometabolic risk factors in type 2 diabetes","volume":"15","author":"Li","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.ard.2026.03.030_bib0011","unstructured":"European Medicines Agency. Xeljanz\u00ae (tofacitinib): summary of product characteristics [Internet]. 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeljanz-epar-product-information_en.pdf; Accessed 13 Feb 2025."},{"key":"10.1016\/j.ard.2026.03.030_bib0012","unstructured":"US Food and Drug Administration. XELJANZ\u00ae (tofacitinib): highlights of prescribing information [Internet]. 2024. Available from: http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=959; Accessed 13 Feb 2025."},{"issue":"1","key":"10.1016\/j.ard.2026.03.030_bib0013","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12969-017-0212-y","article-title":"Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study","volume":"15","author":"Ruperto","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"issue":"10315","key":"10.1016\/j.ard.2026.03.030_bib0014","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","article-title":"Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"398","author":"Ruperto","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ard.2026.03.030_bib0015","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1136\/ard-2023-225094","article-title":"Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study","volume":"83","author":"Brunner","year":"2024","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"10.1016\/j.ard.2026.03.030_bib0016","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.537","article-title":"Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition","volume":"7","author":"Dowty","year":"2019","journal-title":"Pharmacol Res Perspect"},{"issue":"7","key":"10.1016\/j.ard.2026.03.030_bib0017","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.03.030_bib0018","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.reprotox.2022.08.002","article-title":"Lack of direct bone effect of tofacitinib, a JAK inhibitor, in juvenile rats and evaluation of the association between offspring growth and femur length","volume":"113","author":"Campion","year":"2022","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.ard.2026.03.030_bib0019","article-title":"Efficacy and safety of tofacitinib in patients with active systemic juvenile idiopathic arthritis [abstract]","volume":"76","author":"Brunner","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.ard.2026.03.030_bib0020","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/adc.2010.188946","article-title":"Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO)","volume":"96","author":"N","year":"2011","journal-title":"Arch Dis Child"},{"issue":"1","key":"10.1016\/j.ard.2026.03.030_bib0021","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12969-018-0261-x","article-title":"Pediatric Rheumatology Collaborative Study Group - over four decades of pivotal clinical drug research in pediatric rheumatology","volume":"16","author":"Brunner","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.ard.2026.03.030_bib0022","unstructured":"World Health Organization. Length\/height-for-age [Internet]. Available from:https:\/\/www.who.int\/tools\/child-growth-standards\/standards\/length-height-for-age. Accessed 26 Feb 2025."},{"issue":"9","key":"10.1016\/j.ard.2026.03.030_bib0023","doi-asserted-by":"crossref","first-page":"660","DOI":"10.2471\/BLT.07.043497","article-title":"Development of a WHO growth reference for school-aged children and adolescents","volume":"85","author":"de Onis","year":"2007","journal-title":"Bull World Health Organ"},{"issue":"3","key":"10.1016\/j.ard.2026.03.030_bib0024","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0300-595X(86)80005-6","article-title":"Normal growth and techniques of growth assessment","volume":"15","author":"Tanner","year":"1986","journal-title":"Clin Endocrinol Metab"},{"issue":"20","key":"10.1016\/j.ard.2026.03.030_bib0025","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E","article-title":"Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data","volume":"16","author":"Cnaan","year":"1997","journal-title":"Stat Med"},{"issue":"12","key":"10.1016\/j.ard.2026.03.030_bib0026","doi-asserted-by":"crossref","first-page":"5870","DOI":"10.1210\/jcem.86.12.8117","article-title":"Reference values for IGF-I throughout childhood and adolescence: a model that accounts simultaneously for the effect of gender, age, and puberty","volume":"86","author":"Lofqvist","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ard.2026.03.030_bib0027","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.ard.2026.03.030_bib0028","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/acr.23870","article-title":"2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis","volume":"71","author":"Ringold","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.ard.2026.03.030_bib0029","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41584-024-01079-8","article-title":"Treatment of non-systemic juvenile idiopathic arthritis","volume":"20","author":"Shenoi","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2026.03.030_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0324440","article-title":"Effect of biologic treatments on growth in children with juvenile idiopathic arthritis: a systematic review","volume":"20","author":"Makhlouf","year":"2025","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ard.2026.03.030_bib0031","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3899\/jrheum.170326","article-title":"Growth during tocilizumab therapy for polyarticular-course juvenile idiopathic arthritis: 2-year data from a phase III clinical trial","volume":"45","author":"Bharucha","year":"2018","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.ard.2026.03.030_bib0032","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/rheumatology\/keu489","article-title":"Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study","volume":"54","author":"Kearsley-Fleet","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2026.03.030_bib0033","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/art.38984","article-title":"Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial","volume":"67","author":"De Benedetti","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.ard.2026.03.030_bib0034","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/ard.2005.047225","article-title":"Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis","volume":"65","author":"Tynjala","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ard.2026.03.030_bib0035","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1002\/art.27682","article-title":"Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis","volume":"62","author":"Giannini","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.ard.2026.03.030_bib0036","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.pedneo.2024.08.005","article-title":"Biologics promote catch-up growth in young Juvenile idiopathic arthritis patients with lower body height","volume":"66","author":"Hsu","year":"2025","journal-title":"Pediatr Neonatol"},{"issue":"6","key":"10.1016\/j.ard.2026.03.030_bib0037","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","article-title":"Treating juvenile idiopathic arthritis to target: recommendations of an international task force","volume":"77","author":"Ravelli","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2026.03.030_bib0038","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/rheumatology\/key070","article-title":"The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis","volume":"58","author":"Veale","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.ard.2026.03.030_bib0039","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/cei.12234","article-title":"Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis","volume":"175","author":"Migita","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ard.2026.03.030_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1141039","article-title":"Short stature related to Growth Hormone Insensitivity (GHI) in childhood","volume":"14","author":"Mastromauro","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2026.03.030_bib0041","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000541226","article-title":"What is normal growth? Principles, practicalities and pitfalls of growth assessments in infants and children","volume":"80","author":"Fenton","year":"2024","journal-title":"Ann Nutr Metab"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726002165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726002165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:19:25Z","timestamp":1789154365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726002165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0003496726002165"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.03.030","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of tofacitinib on growth in patients with juvenile idiopathic arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.03.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}